Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Cartesian Therapeutics to post earnings of ($0.61) per share and revenue of $0.69 million for the quarter.
Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.07). The business had revenue of $1.10 million for the quarter, compared to analysts' expectations of $0.69 million. On average, analysts expect Cartesian Therapeutics to post $5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Cartesian Therapeutics Stock Up 6.3%
Shares of NASDAQ RNAC traded up $0.62 during mid-day trading on Monday, hitting $10.52. 49,655 shares of the company traded hands, compared to its average volume of 115,819. Cartesian Therapeutics has a 1 year low of $8.85 and a 1 year high of $41.87. The business has a 50 day moving average of $13.09 and a two-hundred day moving average of $17.02. The stock has a market capitalization of $272.86 million, a price-to-earnings ratio of -0.20 and a beta of 0.51.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on RNAC. Needham & Company LLC dropped their price target on Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Cartesian Therapeutics in a research note on Wednesday, April 9th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $42.50.
Read Our Latest Stock Report on Cartesian Therapeutics
Cartesian Therapeutics Company Profile
(
Get Free Report)
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Featured Articles
Before you consider Cartesian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.
While Cartesian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
